2-[2-Chloro-6-(cyclopentylamino)-9-purinyl]-5-(hydroxymethyl)oxolane-3,4-diol

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2-[2-Chloro-6-(cyclopentylamino)-9-purinyl]-5-(hydroxymethyl)oxolane-3,4-diol
• 英文别名: 2-[2-chloro-6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
• 化学式: C₁₅H₂₀ClN₅O₄
• 分子量: 369.8
• InChiKey: XSMYYYQVWPZWIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• A1 adenosine receptor agonists
  申请人：Elzein Elfatih

  公开号：US20060276428A1

  公开（公告）日：2006-12-07

  Disclosed are novel compounds that are partial and full A 1 adenosine receptor agonists having the structure of Formula I: which are useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.

  本发明揭示了具有以下结构式I的部分和完全A1腺苷受体激动剂的新化合物，其可用于治疗各种疾病状态，特别是心动过速和心房颤动、心绞痛和心肌梗死。
• A1 ADENOSINE RECEPTOR AGONISTS
  申请人：Elzein Elfatih

  公开号：US20090156544A1

  公开（公告）日：2009-06-18

  Disclosed are novel compounds that are partial and full A 1 adenosine receptor agonists having the structure of Formula I: which are useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.

  本发明涉及一种新型化合物，其为部分和完全A1腺苷受体激动剂，具有公式I的结构，可用于治疗各种疾病状态，特别是心动过速和心房颤动、心绞痛和心肌梗死。
• COMBINATION COMPOSITIONS OF ADENOSINE A1 AGONISTS AND CARBONIC ANHYDRASE INHIBITORS FOR REDUCING INTRAOCULAR PRESSURE
  申请人：Inotek Pharmaceuticals Corporation

  公开号：EP2555775A1

  公开（公告）日：2013-02-13
• METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION
  申请人：TUFTS UNIVERSITY

  公开号：US20140241990A1

  公开（公告）日：2014-08-28

  Disclosed herein are methods for treating depression and depressive-like symptoms by administering a therapeutically effective amount of an adenosine 1 receptor agonist. Also disclosed herein are methods for identifying adenosine receptor agonists and the use of identified adenosine receptor agonists for treating diseases, disorders or conditions characterized by pathological sleep perturbations.
• US7381714B2
  申请人：——

  公开号：US7381714B2

  公开（公告）日：2008-06-03